| Literature DB >> 31964389 |
Yao Guo1,2, Minmin Sun1,2, Haiyan Chen1,2, Dehong Kong1,2, Xianhong Shu1,2, Cuizhen Pan3,4.
Abstract
BACKGROUND: To evaluate the detailed dynamic change of left ventricular diastolic function (LVDF) by echocardiography in aortic stenosis (AS) patients receiving transcatheter aortic valve implantation (TAVI) and compare LVDF classification according to 2009 ASE/EAE and 2016 ASE/EACVI recommendations.Entities:
Keywords: Diastolic function; Doppler imaging; Transcatheter aortic valve implantation; Transthoracic echocardiography
Mesh:
Year: 2020 PMID: 31964389 PMCID: PMC6975069 DOI: 10.1186/s12947-020-0184-9
Source DB: PubMed Journal: Cardiovasc Ultrasound ISSN: 1476-7120 Impact factor: 2.062
Fig. 1Diagram of the flow of participation
Comparison of echocardiographic parameters according to 2009 and 2016 left ventricular diastolic function recommendations
| 2009/2016 Parameters | 2009 Parameters | 2016 Parameters |
|---|---|---|
| Average E/e’ | Valsalva E/A | E/A + E |
| Septal/Lateral e’ | DT | TR |
| LAVI | Ar-A | LVEF |
| E/A |
LAVI left atria maximum volume index; DT deceleration time of E-wave; TR tricuspid regurgitation systolic peak velocity;
Baseline clinical characteristic of enrolled 35 patients
| Demographic data | |
| Agea (year) | 79.6 ± 4.3 (72–87) |
| Femaleb n (%) | 15 (42.9) |
| BMIa (kg/m2) | 22.9 ± 3.72 |
| Body surface areaa (m2) | 1.68 ± 0.18 |
| Heart ratea (beats/min) | 69.1 ± 10.8 |
| Systolic BPa (mmHg±SD) | 134.5 ± 2.9 |
| Diastolic BPa (mmHg±SD) | 65.7 ± 11.5 |
| Hemoglobina (g/L ± SD) | 114.6 ± 11.3 |
| Creatininea (mmol/L ± SD) | 81.5 ± 21.3 |
| STS scorea (%mortality±SD) | 8.8 ± 4.2 |
| EuroSCOREa | 3.6 ± 1.9 |
| Artificial aortic valveb n (%) | |
| Medtronic Hancock II | 1(2.9) |
| VENUS-A | 23 (65.7) |
| J-Valve | 11 (31.4) |
| Medical historyb n (%) | |
| Hypertension | 17 (48.6) |
| Diabetes | 9(25.7) |
| Coronary heart disease (CHD) | 14 (40) |
| Previous PCI | 3 (8.5) |
| COPD | 6 (17.1) |
| Degree of mitral regurgitationb n (%) | |
| None/Mild | 22 (62.9)/13 (37.1) |
| Mitral annular calcification n (%) | 17 (48.6) |
| NYHA functional classificationb n (%) | |
| I/II/III/IV | 0/8 (22.9)/24 (68.6)/3 (8.5) |
| Diastolic dysfunctionb n (%) | |
| Normal/I/II/ III/Indeterminate | 7 (20)/7 (20)/14 (40)/5 (14)/2 (6) |
BP blood pressure; STS society of thoracic surgeons; PCI percutaneous coronary intervention; COPD chronic obstructive pulmonary disease; NYHA New York Heart Association;
aData are mean ± SD with range in parentheses
bData are raw number with percentage in parentheses
Baseline and follow-up echocardiographic variables, pre- and post-TAVI
| Baseline | Post-3d | Post-1 m | Post-6 m | ||||
|---|---|---|---|---|---|---|---|
| LVEDD (mm) | 51.7 ± 7.2 | 50.6 ± 6.3 | 50.6 ± 6.4 | 48.9 ± 5.0 | 0.336 | 0.143 | 0.004* |
| LVESD (mm) | 36.4 ± 8.0 | 36.0 ± 8.4 | 35.7 ± 5.3 | 33.3 ± 4.1 | 0.669 | 0.604 | 0.008* |
| IVST (mm) | 13.4 ± 1.6 | 12.8 ± 2.2 | 12.7 ± 1.7 | 11.9 ± 1.3 | 0.028* | 0.014* | 0.001* |
| LVPWT (mm) | 12.3 ± 0.8 | 11.5 ± 1.3 | 11.7 ± 1.1 | 11.1 ± 1.3 | 0.002* | 0.080 | 0.003* |
| LVEF-2D (%) | 52.5 ± 10.1 | 56.7 ± 12.8 | 58.7 ± 7.3 | 61.5 ± 6.6 | 0.014* | 0.001* | < 0.001* |
| LVMI (g/m2) | 103.9 ± 12.5 | 103 ± 12.3 | 91.5 ± 11.9 | 84.3 ± 10.7 | 0.667 | < 0.001* | < 0.001* |
| Peak VG (mmHg) | 102.8 ± 31.1 | 21.9 ± 8.9 | 24.7 ± 7.4 | 21.5 ± 7.4 | < 0.001* | < 0.001* | < 0.001* |
| Mean VG (mmHg) | 58.4 ± 16.8 | 11.6 ± 4.5 | 12.4 ± 3.8 | 10.8 ± 3.9 | < 0.001* | < 0.001* | < 0.001* |
| Peak velocity (m/s) | 4.9 ± 0.6 | 2.2 ± 0.5 | 2.4 ± 0.3 | 2.2 ± 0.4 | < 0.001* | < 0.001* | < 0.001* |
| SPAP (mmHg) | 46.5 ± 14.6 | 38.5 ± 9.5 | 37.1 ± 8.6 | 36.6 ± 6.2 | 0.022* | 0.003* | 0.004* |
LVEDD left ventricular end-diastolic diameter; LVESD left ventricular end-systolic diameter; IVST interventricular septum thickness; LVPWT left ventricular posterior wall thickness; LVMI left ventricular mass index; VG valve gradient; SPAP systolic pulmonary arterial pressure
Data are mean ± SD
P1: for comparison between baseline and Post-3d; P2: for comparison between baseline and Post-1 m; P3: for comparison between baseline and Post-6 m. *Data are P < 0.05
Echocardiographic diastolic variables, pre- and post-TAVI
| Baseline | Post-3d | Post-1 m | Post-6 m | ||||
|---|---|---|---|---|---|---|---|
| E (cm/s) | 66.3 ± 18.6 | 67.7 ± 16.9 | 66.0 ± 20.8 | 66.5 ± 15.8 | 0.582 | 0.561 | 0.850 |
| A (cm/s) | 81.4 ± 22.7 | 86.9 ± 26.7 | 87.5 ± 23.2 | 85.5 ± 20.4 | 0.072 | 0.882 | 0.585 |
| E/A | 0.9 ± 0.4 | 0.8 ± 0.4 | 0.8 ± 0.3 | 0.9 ± 0.3 | 0.959 | 0.491 | 0.896 |
| DT (ms) | 216.2 ± 50.6 | 188.1 ± 39.3 | 193.0 ± 34.0 | 196.4 ± 26.4 | 0.003* | 0.540 | 0.514 |
| IVRT(ms) | 107.1 ± 12.1 | 91.0 ± 12.3 | 84.6 ± 9.1 | 82.8 ± 9.3 | < 0.001* | 0.007* | 0.273 |
| E’ (cm/s) | 6.5 ± 2.1 | 6.9 ± 1.8 | 8.0 ± 2.3 | 8.6 ± 1.6 | 0.356 | 0.018* | 0.047* |
| E/E’ | 10.8 ± 3.7 | 10.3 ± 3.3 | 7.9 ± 3.0 | 7.2 ± 2.1 | 0.403 | 0.012* | 0.063 |
| LA area (cm2) | 22.9 ± 4.6 | 21.4 ± 3.8 | 18.6 ± 3.0 | 17.2 ± 2.3 | < 0.001* | < 0.001* | < 0.001* |
| LAVI (ml/cm2) | 42.4 ± 14.7 | 38.7 ± 11.3 | 31.3 ± 8.3 | 27.5 ± 5.5 | 0.008* | < 0.001* | < 0.001* |
| TR (m/s) | 3.3 ± 0.5 | 2.9 ± 0.5 | 2.7 ± 0.4 | 2.6 ± 0.3 | < 0.001* | 0.021* | 0.143 |
E, early transmitral flow velocity; A, late transmitral flow velocity; DT deceleration time of E-wave; IVRT isovolumic relaxation time; E′, mean peak early diastolic myocardial annular velocity; TR tricuspid regurgitation systolic peak velocity; LA left atrial; LAVI left atria maximum volume index
Data are mean ± SD
P1: for comparison between baseline and Post-3d; P2: for comparison between Post-3d and Post-1 m; P3: for comparison between Post-1 m and Post-6 m. *Data are P < 0.05
Fig. 2broken line graphs show the distributions and variation of E/e’, TR, LA area, LAVI, IVRT and DT on one day before TAVI and on the third day, in the first-, and six- month after TAVI
Fig. 3Bar graphs show the distributions of LVDD grading according to 2009 ASE/ EAE and 2016 ASE/EACVI recommendations
Fig. 4Changes in LVDD groups after the reevaluation between the 2009 ASE/EAE recommendations (left) and the 2016 ASE/EACVI recommendations (right)
Fig. 5The Bland-Altman analysis of E’, E/e’, IVRT, TR, LA area and LAVI